French pharma major Sanofi (Euronext: SAN) has entered into a worldwide license agreement with South Korea’s Hanmi Pharmaceutical to develop a portfolio of experimental, long-acting diabetes treatments.
Under the terms of the accord, Hanmi will receive an upfront payment of 400 million euros ($434.4 million) and is eligible for up to 3.5 billion euros in development, registration and sales milestones, as well as double-digit royalties on net sales. The agreement is subject to customary closing conditions including review under the Hart-Scott-Rodino Antitrust Improvements Act.
Deal includes late-stage agent efpeglenatide
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze